JP2010539082A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539082A5 JP2010539082A5 JP2010524063A JP2010524063A JP2010539082A5 JP 2010539082 A5 JP2010539082 A5 JP 2010539082A5 JP 2010524063 A JP2010524063 A JP 2010524063A JP 2010524063 A JP2010524063 A JP 2010524063A JP 2010539082 A5 JP2010539082 A5 JP 2010539082A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- complex according
- cyclodextrin
- complex
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97105607P | 2007-09-10 | 2007-09-10 | |
| US60/971,056 | 2007-09-10 | ||
| PCT/US2008/056393 WO2009035718A1 (en) | 2007-09-10 | 2008-03-10 | Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010539082A JP2010539082A (ja) | 2010-12-16 |
| JP2010539082A5 true JP2010539082A5 (enExample) | 2011-03-24 |
| JP5474792B2 JP5474792B2 (ja) | 2014-04-16 |
Family
ID=40452375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010524063A Expired - Fee Related JP5474792B2 (ja) | 2007-09-10 | 2008-03-10 | 亜鉛結合部分を含むキナゾリンベースｅｇｆｒインヒビターの酒石酸塩またはその複合体 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7846938B2 (enExample) |
| EP (1) | EP2190287B1 (enExample) |
| JP (1) | JP5474792B2 (enExample) |
| AU (1) | AU2008299896B2 (enExample) |
| CA (1) | CA2698944C (enExample) |
| ES (1) | ES2526718T3 (enExample) |
| WO (1) | WO2009035718A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8604044B2 (en) | 2006-09-11 | 2013-12-10 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| CN101570516B (zh) * | 2009-04-14 | 2011-01-05 | 重庆威尔德·浩瑞医药化工有限公司 | 一种制备4-(3-氯-4-氟苯基胺基)-7-甲氧基-6-[3-(4-吗啉基)丙氧基]喹唑啉的方法 |
| CN102452988B (zh) * | 2010-10-27 | 2016-01-27 | 中国科学院化学研究所 | 一种喹唑啉衍生物及其制备方法 |
| EP2685980B1 (en) | 2011-03-17 | 2017-12-06 | The Trustees Of The University Of Pennsylvania | Methods and use of bifunctional enzyme-building clamp-shaped molecules |
| WO2012125904A1 (en) | 2011-03-17 | 2012-09-20 | The Trustees Of The University Of Pennsylvania | Mutation mimicking compounds that bind to the kinase domain of egfr |
| US20140229256A1 (en) | 2013-02-11 | 2014-08-14 | Solutran | Product substantiation using approved product list system and method |
| CN102276500A (zh) * | 2011-05-05 | 2011-12-14 | 西安交通大学 | 水杨酰胺类抗肿瘤化合物及其合成方法和用途 |
| CA2846066A1 (en) * | 2011-10-28 | 2013-05-02 | Chong Kun Dang Pharmaceutical Corp. | Hydroxamate derivatives for hdac inhibitor, and the pharmaceutical composition comprising thereof |
| WO2013159698A1 (zh) * | 2012-04-26 | 2013-10-31 | 深圳信立泰药业股份有限公司 | 稠环喹唑啉羟肟酸类化合物及其作为抗肿瘤药物的应用 |
| CN102898315B (zh) * | 2012-11-05 | 2015-01-28 | 上海毕得医药科技有限公司 | 3-乙炔基-4-氟苯胺的制备方法 |
| US10552861B2 (en) | 2013-02-11 | 2020-02-04 | Solutran, Inc. | Dual redemption path with shared benefits system and method |
| MY182793A (en) * | 2014-08-08 | 2021-02-05 | Forsight Vision4 Inc | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
| CN105693630B (zh) * | 2016-03-10 | 2018-02-16 | 田静 | 一种吉非替尼中间体的制备方法 |
| EP4025559A4 (en) * | 2019-09-08 | 2023-05-10 | Hadasit Medical Research Services and Development Ltd. | ANTIFIBROTIC COMPOUNDS AND USES THEREOF |
| US12100049B2 (en) | 2020-06-05 | 2024-09-24 | Soltran, LLC | Filtered POS processing of services |
| EP4281449A1 (en) * | 2021-01-20 | 2023-11-29 | Lightox Limited | Protected hdac (histone deacetylase) inhibitors |
| US12530346B2 (en) | 2021-12-24 | 2026-01-20 | Solutran, LLC | Data transmission filtering through a customized filter list |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| ATE174908T1 (de) * | 1993-05-26 | 1999-01-15 | Sumitomo Pharma | Chinazolinonderivate |
| GB9508537D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| WO1997030035A1 (en) | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
| BRPI0017548B8 (pt) | 1999-02-10 | 2023-05-02 | Astrazeneca Ab | Composto |
| US7230000B1 (en) * | 1999-10-27 | 2007-06-12 | Cytokinetics, Incorporated | Methods and compositions utilizing quinazolinones |
| UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| DE60214828T2 (de) | 2001-02-26 | 2007-09-06 | Mcgill University, Montreal | Kombi-moleküle, welche eine inhibierende wirkung auf die signalübertragung und dna-schädigende eigenschaften haben |
| CN1688549A (zh) | 2002-08-23 | 2005-10-26 | 麒麟麦酒株式会社 | 具有TGFβ抑制活性的化合物和含所述化合物的药用组合物 |
| US7250514B1 (en) | 2002-10-21 | 2007-07-31 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| KR20050122199A (ko) * | 2003-01-23 | 2005-12-28 | 티.케이. 시그널 리미티드 | 표피성장인자 수용체 티로신 키나제의 비가역성 억제제 및 그의 용도 |
| PE20040945A1 (es) * | 2003-02-05 | 2004-12-14 | Warner Lambert Co | Preparacion de quinazolinas substituidas |
| MXPA06003341A (es) * | 2003-09-25 | 2006-06-08 | Astrazeneca Ab | Derivados de quinazolina. |
| GB0322409D0 (en) * | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
| WO2005097134A2 (en) | 2004-03-31 | 2005-10-20 | The Scripps Research Institute | Quinazoline based protein kinase inhibitors |
| EP2946810A1 (en) | 2005-02-03 | 2015-11-25 | TopoTarget UK Limited | Combination therapy using an HDAC inhibitor and Vincristine for treating cancer |
| BRPI0607537A2 (pt) * | 2005-04-12 | 2009-09-15 | Elan Pharma Int Ltd | formulações de derivado de quinazolina nanoparticulado |
| MX2007012836A (es) | 2005-04-14 | 2008-01-11 | Novartis Vaccines & Diagnostic | 2-amino-quinazolin-5-onas como inhibidores de la familia hsp90 que son utiles en el tratamiento de enfermedades de proliferacion. |
| ITMI20050729A1 (it) * | 2005-04-22 | 2006-10-23 | Endura Spa | Nuova formulazione biologicamente attiva |
| WO2007131364A1 (en) | 2006-05-16 | 2007-11-22 | Mcgill University | Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties |
| US8604044B2 (en) * | 2006-09-11 | 2013-12-10 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| EP2061469B8 (en) | 2006-09-11 | 2014-02-26 | Curis, Inc. | Quinazoline based egfr inhibitors |
| US20080221132A1 (en) | 2006-09-11 | 2008-09-11 | Xiong Cai | Multi-Functional Small Molecules as Anti-Proliferative Agents |
| US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| EP2049483A2 (en) | 2006-10-28 | 2009-04-22 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| US8119616B2 (en) | 2007-09-10 | 2012-02-21 | Curis, Inc. | Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety |
-
2008
- 2008-03-10 JP JP2010524063A patent/JP5474792B2/ja not_active Expired - Fee Related
- 2008-03-10 ES ES08743752.1T patent/ES2526718T3/es active Active
- 2008-03-10 WO PCT/US2008/056393 patent/WO2009035718A1/en not_active Ceased
- 2008-03-10 CA CA2698944A patent/CA2698944C/en not_active Expired - Fee Related
- 2008-03-10 EP EP08743752.1A patent/EP2190287B1/en active Active
- 2008-03-10 AU AU2008299896A patent/AU2008299896B2/en not_active Ceased
- 2008-09-10 US US12/207,833 patent/US7846938B2/en not_active Expired - Fee Related
-
2010
- 2010-11-08 US US12/941,812 patent/US20110053963A1/en not_active Abandoned
-
2013
- 2013-05-22 US US13/900,165 patent/US8846912B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511467A5 (enExample) | ||
| JP2011511073A5 (enExample) | ||
| TWI594986B (zh) | Antineoplastic agent effect enhancer | |
| JP2012505916A5 (enExample) | ||
| JP2010523476A5 (enExample) | ||
| JP2009533482A5 (enExample) | ||
| JP2017509586A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2012506381A5 (enExample) | ||
| JP2014512356A5 (enExample) | ||
| JP2005500300A5 (enExample) | ||
| JP2013189456A5 (enExample) | ||
| JP2010526814A5 (enExample) | ||
| JP2006503919A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| JP2017530171A5 (enExample) | ||
| JP2012526766A5 (enExample) | ||
| JP2012180344A5 (enExample) | ||
| JP2014518544A5 (enExample) | ||
| JP2015512943A5 (enExample) | ||
| HRP20160545T1 (hr) | Inhibitor fosfoinozitid 3-kinaze sa dijelom koji veže cink | |
| JP2017524013A5 (enExample) | ||
| RU2019110876A (ru) | Композиции, содержащие источник металла, дитиокарбамат и циклодекстрин | |
| JP2010528122A5 (enExample) | ||
| JP2010530002A5 (enExample) |